Project Grant K99HL177179
Award Date 8/1/25
Completion Date 5/31/27
Dollars Obligated $126K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Durham, NC 27708, USA
Similar Awards
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute, Inc. to investigate the genetic basis and underlying mechanisms of heart failure. The research leverages high-throughput cellular analysis techniques, including cell painting and Perturb-seq, to functionally characterize genetic variants associated with heart failure risk. The goal is to rapidly...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $496,367.00 to Duke University to support research on novel approaches for cardiac reprogramming. Specifically, the project aims to improve the efficacy of in-situ reprogramming of scar fibroblasts into cardiomyocytes through three key objectives: Investigating the mechanism by which a repressor complex inhibits cardiomyocyte gene expression, including testing...
- This federal Project Grant award of $680,583.00 from the National Heart Lung and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) supports research to discover genetic modifiers and novel therapies for anthracycline-induced cardiotoxicity. The study aims to use zebrafish models to test candidate genes identified from human genome-wide association studies, as well as explore the role of aging-associated epicardial remodeling in cardiotoxicity. Key areas of focus include...
- The National Heart Lung and Blood Institute (NHLBI) awarded a $711,039 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Research Institute at Nationwide Children's Hospital. The award supports research to determine the functions of the cardiac m6A methyltransferases METTL3 and METTL14 in early myocardial development, and whether their dysregulation contributes to the pathogenesis of fetal dilated cardiomyopathy (DCM). The proposed study leverages mouse...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is funding research to discover novel biomarkers and biological mechanisms underlying early-stage heart failure (HF). The $147,486 award to Duke University will support the development of an automated computational phenotype to identify early-stage HF, which will then be applied to large population cohorts. The research aims to leverage multi-omics data integration and...
- This federal Project Grant award for $802,301, provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research by Weill Medical College of Cornell University to investigate the mechanisms that control the bone marrow "niche" environment and its role in expanding mutated blood stem cells that increase the risk of cardiovascular disease and cancer. The research aims to identify signaling pathways that can be targeted to prevent...
- This Project Grant award of $706,519 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the regulatory role of the NIPBL gene in human cardiac cells. The grant recipient, the University of Pittsburgh, is using an inducible NIPBL depletion human induced pluripotent stem cell model to study NIPBL's function as a transcription regulator in cardiomyocytes. The research aims to elucidate the mechanisms by which NIPBL...
- The Project Grant award titled "IPEDIHEART: INTERDISCIPLINARY RESEARCH TRAINING PROGRAM FOR PEDIATRIC HEART DISEASE" is funded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) for $200,938 from September 1, 2025 to August 31, 2030. The grant supports an interdisciplinary research training program at Duke University focused on advancing scientific understanding and treatment of pediatric and congenital heart diseases. The program aims to...
- This federal Project Grant award of $165,366 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the role of transcription factors KLF2 and KLF4 in cardiac fibroblast function and their relationship to heart failure. The award was granted to Drexel University, a private research university in Pennsylvania, to conduct this research from September 1, 2025 through August 31, 2030. The project aims to advance the...
- The University of Colorado-Denver received a $553,217 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) on August 15, 2025. The grant supports research on the "HAT-Dependent Control of Cardiac Fibrosis" to investigate the role of epigenetic regulatory proteins in controlling the activation of cardiac fibroblasts and development of cardiac fibrosis, which contributes to diastolic dysfunction and heart failure. The...